Pulmonary Pharmacology

1st Edition, Volume 98 - August 1, 2023
Editor: W.S Fred Wong
Language: English
Hardback ISBN:
9 7 8 - 0 - 4 4 3 - 1 8 8 8 0 - 0
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 1 8 8 8 1 - 7

Pulmonary Pharmacology, Volume 98 provides in-depth reviews on the latest progresses about respiratory drug discovery and development. Topics covered in this volume include c… Read more

Purchase options

Limited Offer

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

Pulmonary Pharmacology, Volume 98 provides in-depth reviews on the latest progresses about respiratory drug discovery and development. Topics covered in this volume include corticosteroids, monoclonal antibodies, tyrosine kinase inhibitors and phosphodiesterase inhibitors for the treatments of asthma, COPD or pulmonary fibrosis, with perspective on the development of novel therapeutic strategies such as renin-angiotensin system modulators, mitochondrial function modulators, and non-antibacterial macrolides. Part of the volume is devoted to senotherapy for lung ageing in respiratory diseases, and novel pulmonary delivery technologies, including inhaled biologics.

Cover image
Title page
Table of Contents
Advances in PHARMACOLOGY
Copyright
Contributors
Preface
Abbreviations
Chapter One: Genomic and non-genomic effects of glucocorticoids in respiratory diseases
Abstract
Abbreviations
1 Introduction
2 Genomic mechanisms of action: GR activation
3 GR transactivation or transrepression-mediated mechanisms of action of GCs
4 Non-genomic mechanisms of action of GCs
5 Conclusion
Acknowledgements
References
Chapter Two: Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment
Abstract
Abbreviation
1 Introduction
2 IL-5
3 Mepolizumab
4 Reslizumab
5 Benralizumab
6 IL-4 and IL-13
7 Dupilumab
8 Future developments
9 Conclusion
Conflicts of interest
References
Chapter Three: Phosphodiesterase inhibitors and lung diseases
Abstract
Abbreviations
1 Introduction
2 Conclusion
Conflict of interest statement
References
Chapter Four: Prospects for macrolide therapy of asthma and COPD
Abstract
Abbreviations
1 Introduction
2 Why asthma and COPD
3 What non-antimicrobial macrolide actions are relevant
4 Can antibiosis with macrolides be circumvented
5 Conclusion
Acknowledgments
References
Note in proof
Chapter Five: Targeting the renin angiotensin system for respiratory diseases
Abstract
Abbreviations
1 Introduction
2 Tareting renin angiotensin system in asthma
3 Targeting renin angiotensin system in COPD
4 Targeting renin angiotensin system in pulmonary fibrosis
5 Targeting renin angiotensin system in acute lung injury
6 Conclusion
References
Chapter Six: Progress in the development of kinase inhibitors for treating asthma and COPD
Abstract
Abbreviations
1 Introduction
2 Conclusion
Conflict of interest statement
References
Chapter Seven: Anti-fibrotic strategies and pulmonary fibrosis
Abstract
Abbreviations
1 Introduction
2 IPF pathogenesis: Initiation of fibrogenesis
3 Pathways implicated in fibrosis
4 Growth factor and cytokine activation in IPF
5 Mechanotransduction and Hippo activation
6 Cellular players in IPF
7 IPF models
8 IPF drug treatment
9 Recommended drugs for IPF: Pirfenidone and nintedanib
10 Conclusion
References
Chapter Eight: Novel treatments against airway inflammation in COPD based on drug repurposing
Abstract
Abbreviations
1 Introduction
2 The novel pharmacologic targets
3 Conclusion
Acknowledgements
References
Chapter Nine: Senotherapy for lung diseases
Abstract
Abbreviations
1 Introduction
2 Senotherapy for lung disease
3 Conclusion
Conflict of interest
References
Chapter Ten: Delivery technology of inhaled therapy for asthma and COPD
Abstract
Abbreviations
1 Introduction
2 Inhaled therapy for asthma and COPD
3 Challenges and barriers of drug delivery to the lung
4 Aerosol drug delivery
5 Inhaler devices: their merits and limitations
6 Recent development – biologics for inhalation
7 Conclusion
References

W.S Fred Wong

Dr. W.S. Fred Wong received his BPharm (with cum laude) from the St. Johns’ University in New York, and his PhD in Pharmacology from The Ohio State University in Columbus, Ohio. He moved to Lilly Research Laboratories at Indianapolis as a postdoctoral scientist with research focus on respiratory drug development and then to Respiratory and Critical Care Medicine Division at the Brigham and Women’s Hospital in Boston as a Research Fellow in Medicine. After that, Dr. Wong joined the Department of Pharmacology at The National University of Singapore (NUS) and since built the Respiratory Pharmacology Laboratory. Dr. Wong is a Professor of Pharmacology, former Head of the Department, and former Assistant Dean and Vice Dean of the Yong Loo Lin School of Medicine, National University of Singapore. He is the Director of the Drug Discovery and Optimization Platform (DDOP) in the Yong Loo Lin School of Medicine. He is the Principal Investigator of the Singapore-HUJ Alliance for Research and Enterprise (SHARE). Dr. Wong is the founding President of the Singapore Pharmacological Society. His research interest is to identify therapeutic targets and to discover and develop pharmacological agents for the treatment of airway inflammation, oxidative and DNA damage and remodeling in asthma and in COPD, using small molecule drugs, herbal medicinal bioactive molecules, antisense oligonucleotides (ASO)/siRNA technology, and pharmacoproteomics and metabolomics approaches. He has published a series of mechanism-based drug discovery studies targeting at tyrosine kinases, p38 MAPK, ERK1/2, PI3K, GSK-3, RIP2, RPS3 and AT2R responsible for asthma and COPD pathogenesis, that have paved the way for further investigation and innovative development of specific therapeutic strategies for asthma and COPD. Natural compounds like the diterpenoid lactone andrographolide and calcaratarin D, vitamin E isoform -tocotrienol, and anti-malarial drug artesunate were first reported by his laboratory to possess anti-inflammatory actions in both asthma and COPD. His laboratory has also identified lungkine, ApoL2 and house dust mite-induced DNA damage as potential mechanisms for asthma pathogenesis.

Affiliations and expertise

Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore